Quince Therapeutics, Inc. Logo

Quince Therapeutics, Inc.

Late-stage biotech developing red blood cell-encapsulated drugs for rare diseases.

QNCX | US

Overview

Corporate Details

ISIN(s):
US22053A1079
LEI:
Country:
United States of America
Address:
611 GATEWAY BLVD., SUITE 273, 94080 SOUTH SAN FRANCISCO
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Quince Therapeutics, Inc. is a late-stage biotechnology company focused on developing and commercializing therapeutics for rare diseases. The company's core technology is its proprietary Autologous Intracellular Drug Encapsulation (AIDE) platform, a novel drug/device combination that encapsulates drugs within a patient's own red blood cells. This delivery system is designed to improve tolerability, enhance tissue biodistribution, and reduce the adverse effects of potent medicines. Quince's lead product candidate, eDSP, is in a pivotal Phase 3 clinical trial for the treatment of Ataxia-Telangiectasia (A-T), a rare pediatric neurodegenerative disease with no currently approved therapies. The eDSP System has received Fast Track designation from the U.S. Food and Drug Administration.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Quince Therapeutics, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Quince Therapeutics, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Quince Therapeutics, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Sensei Biotherapeutics, Inc. Logo
Developing tumor-activated biologics to stimulate a targeted immune response against cancer.
United States of America
SNSE
Senti Biosciences, Inc. Logo
Developing smart cell and gene therapies with Gene Circuits to precisely target cancer.
United States of America
SNTI
SEOUL PHARMA CO.,LTD Logo
Develops pharmaceuticals with innovative Orally Disintegrating Film (ODF) tech for global markets.
South Korea
018680
Septerna, Inc. Logo
Advancing novel small molecule GPCR medicines for endocrine, immune, and metabolic diseases.
United States of America
SEPN
SERA PROGNOSTICS, INC. Logo
Develops predictive blood tests to assess preterm birth risk and improve pregnancy outcomes.
United States of America
SERA
Seres Therapeutics, Inc. Logo
Developing live biotherapeutics from the microbiome to treat infections and immune diseases.
United States of America
MCRB
Serina Therapeutics, Inc. Logo
Developing safer, more effective drugs for neurology and cancer using polymer technology.
United States of America
SER
SEYİTLER KİMYA SANAYİ A.Ş. Logo
Manufacturer of medical tapes, wound dressings, and first aid plasters for the healthcare industry.
Türkiye
SEYKM
Shaperon Inc. Logo
Develops inflammasome inhibitors & nanobodies for inflammatory diseases and cancer.
South Korea
378800
Shattuck Labs, Inc. Logo
Clinical-stage biotech developing novel biologic medicines for inflammatory & autoimmune diseases.
United States of America
STTK

Talk to a Data Expert

Have a question? We'll get back to you promptly.